Skip to content

International Point Prevalence Study of Intensive Care Unit Transfusion Practices

International Point Prevalence Study of Intensive Care Unit Transfusion Practices - the InPUT study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON28052
Enrollment
3000
Registered
2020-11-16
Start date
2020-03-02
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

All patients = 18 years admitted to the adult Intensive Care Unit.

Interventions

None listed

Sponsors

AMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients are included in the study if they are aged 18 years and older and are newly admitted to the ICU during the course of a pre-specified week (7 days).

Exclusion criteria

Exclusion criteria: All patients younger than 18 years old No informed consent in countries where no opt-out procedure applies.

Design outcomes

Primary

MeasureTime frame
Our objective is to quantify international transfusion practice in ICUs. We will be looking at transfusion and administration of RBCs, platelets, plasma and several coagulation agents (pro-coagulant and anti-fibrinolytic) in correlation to clinical parameters and corresponding laboratory values. Differences within and between regions will be studied.

Secondary

MeasureTime frame
Secondary objectives will include the following: - To evaluate the effect of physiological triggers on transfusion practice; - To evaluate the effect of transfusion on corresponding hematology laboratory variables; - To compare transfusion practice in different patient subgroups, e.g. septic shock and coronary disease; - To evaluate the association of transfusion thresholds applied and clinical outcomes (e.g. 28-day mortality).

Contacts

Public ContactAlexander Vlaar

Amsterdam UMC, location AMC

inputstudy@amsterdamumc.nl+31205669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)